Clinical Trial

SH-1028 Tablets Versus Placebo as Adjuvant Therapy in Resected Stage II-IIIB NSCLC With Sensitizing EGFR Mutations

Name: SH-1028 Tablets Versus Placebo as Adjuvant Therapy in Resected Stage II-IIIB NSCLC With Sensitizing EGFR Mutations — clinical trial record (NCT06080776)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Recruiting Phase 3

View on ClinicalTrials.gov →

Summary

To assess the efficacy and safety of SH-1028 tablets versus placebo in stage II-IIIB non-small cell lung cancer (NSCLC) patients with sensitizing epidermal growth factor receptor (EGFR) mutations, following complete tumor resection, with or without adjuvant chemotherapy.

Trial Details

NCT Number	NCT06080776
Lead Sponsor	Nanjing Sanhome Pharmaceutical, Co., Ltd.
Conditions	Non-small Cell Lung Cancer
Enrollment	242 participants
Start Date	2023-05-11
Primary Completion	2028-02-01 (estimated)
Study Completion	2031-02-01 (estimated)
Updated on ClinicalTrials.gov	2023-10-12